Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C54H92O23 |
Molecular Weight | 1109.2945 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 30 / 30 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(CC[C@]2(C)[C@]1([H])[C@H](O)C[C@]3([H])[C@@]4(C)CC[C@H](O[C@]5([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O[C@]6([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)C(C)(C)[C@]4([H])CC[C@@]23C)[C@](C)(CCC=C(C)C)O[C@@H]7O[C@H](CO[C@@H]8O[C@H](CO)[C@@H](O)[C@H](O)[C@H]8O)[C@@H](O)[C@H](O)[C@H]7O
InChI
InChIKey=GZYPWOGIYAIIPV-JBDTYSNRSA-N
InChI=1S/C54H92O23/c1-23(2)10-9-14-54(8,77-48-44(69)40(65)37(62)29(74-48)22-70-46-42(67)38(63)34(59)26(19-55)71-46)24-11-16-53(7)33(24)25(58)18-31-51(5)15-13-32(50(3,4)30(51)12-17-52(31,53)6)75-49-45(41(66)36(61)28(21-57)73-49)76-47-43(68)39(64)35(60)27(20-56)72-47/h10,24-49,55-69H,9,11-22H2,1-8H3/t24-,25+,26+,27+,28+,29+,30-,31+,32-,33-,34+,35+,36+,37+,38-,39-,40-,41-,42+,43+,44+,45+,46+,47-,48-,49-,51-,52+,53+,54-/m0/s1
Molecular Formula | C54H92O23 |
Molecular Weight | 1109.2945 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 30 / 30 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: Description was created based on several sources, including https://www.lktlabs.com/product/ginsenoside-rb1/
https://www.ncbi.nlm.nih.gov/pubmed/25120573
Curator's Comment: Description was created based on several sources, including https://www.lktlabs.com/product/ginsenoside-rb1/
https://www.ncbi.nlm.nih.gov/pubmed/25120573
Ginsenoside Rb1 is a triterpene saponin originally found in species of Panax that exhibits antioxidative, anti-inflammatory, neuroprotective, orexigenic, and stimulatory activities. In animal models, ginsenoside Rb1 increases motor activity, food intake, and skeletal muscle ATP content, improving energy metabolism. Ginsenoside Rb1 also downregulates expression of toll-like receptor 4 (TLR4) and TNF-α in animal models of sepsis, protecting against liver and lung damage. Additionally, ginsenoside Rb1 inhibits glucose-induced neurotoxicity by preventing GSK-3β-stimulated CHOP induction. This compound also activates Nrf2 and increases expression of heme oxygenase 1 (HO-1), suppressing oxidative stress in vitro. Ginsenoside Rb1 improves learning and memory, increases Bmax of M-cholinergic receptors, and accelerates cerebral protein and ACh biosynthesis. Ginsenoside Rb1 is a component of Korean Red Ginseng, marketed in Korea. Korean ginseng (Panax ginseng Meyer, Araliaceae) is traditionally used as an important herbal medicine in Far East Asia. Korean Red Ginseng is possibly effective for:
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27060612 | https://www.ncbi.nlm.nih.gov/pubmed/15663889
Curator's Comment: Ginsenoside Rb1 improves learning and memory, increases Bmax of M-cholinergic receptors, and accelerates cerebral protein and ACh biosynthesis.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0006915 |
|||
Target ID: GLP1 secretion Sources: https://www.ncbi.nlm.nih.gov/pubmed/23444389 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Inhibition by ginsenosides Rb1 and Rg1 of methamphetamine-induced hyperactivity, conditioned place preference and postsynaptic dopamine receptor supersensitivity in mice. | 1998 May |
|
Prediction of estrogen receptor agonists and characterization of associated molecular descriptors by statistical learning methods. | 2006 Nov |
|
Ginsenoside Rb1 inhibits osteoclastogenesis by modulating NF-κB and MAPKs pathways. | 2012 May |
|
Effects of Astragaloside IV combined with the active components of Panax notoginseng on oxidative stress injury and nuclear factor-erythroid 2-related factor 2/heme oxygenase-1 signaling pathway after cerebral ischemia-reperfusion in mice. | 2014 Oct |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01761227
To treat vascular dementia:
Fufangdanshen tablet contains ginsenoside Rb1 3.03mg, as well as tanshinoneⅡA 0.67mg , salvianolic acid B 8.2mg, Panax Notoginsenosides R1 0.53mg, ginsenoside Rg1 2.73mg. 3 tablets per time, 3 times per day for 24 weeks
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25120573
Compared with the control group, GS-Rb1 from 2.5 to 40 uM incubation increased viability of neonatal rat cardiomyocytes from 31.7%±1.3% to 53.3%±1.7%.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 02:15:47 GMT 2023
by
admin
on
Sat Dec 16 02:15:47 GMT 2023
|
Record UNII |
7413S0WMH6
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
Ginsenoside Rb1
Created by
admin on Sat Dec 16 02:15:47 GMT 2023 , Edited by admin on Sat Dec 16 02:15:47 GMT 2023
|
PRIMARY | |||
|
7413S0WMH6
Created by
admin on Sat Dec 16 02:15:47 GMT 2023 , Edited by admin on Sat Dec 16 02:15:47 GMT 2023
|
PRIMARY | |||
|
310103
Created by
admin on Sat Dec 16 02:15:47 GMT 2023 , Edited by admin on Sat Dec 16 02:15:47 GMT 2023
|
PRIMARY | |||
|
DB06749
Created by
admin on Sat Dec 16 02:15:47 GMT 2023 , Edited by admin on Sat Dec 16 02:15:47 GMT 2023
|
PRIMARY | |||
|
9898279
Created by
admin on Sat Dec 16 02:15:47 GMT 2023 , Edited by admin on Sat Dec 16 02:15:47 GMT 2023
|
PRIMARY | |||
|
41753-43-9
Created by
admin on Sat Dec 16 02:15:47 GMT 2023 , Edited by admin on Sat Dec 16 02:15:47 GMT 2023
|
PRIMARY | |||
|
1291661
Created by
admin on Sat Dec 16 02:15:47 GMT 2023 , Edited by admin on Sat Dec 16 02:15:47 GMT 2023
|
PRIMARY | |||
|
DTXSID401316929
Created by
admin on Sat Dec 16 02:15:47 GMT 2023 , Edited by admin on Sat Dec 16 02:15:47 GMT 2023
|
PRIMARY | |||
|
67989
Created by
admin on Sat Dec 16 02:15:47 GMT 2023 , Edited by admin on Sat Dec 16 02:15:47 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
USP
|
||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
USP
|
||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
USP
|